Return to homepagePandemic Pact

Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 4P01AI165066-02

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2027

  • Known Financial Commitments (USD)

    $285,928

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    ASSOCIATE PROFESSOR Daniel Kulp

  • Research Location

    United States of America

  • Lead Research Institution

    WISTAR INSTITUTE

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project Summary The first project of our pan-CoV proposal is titled 'Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites'. Our team's expertise will culminate in structurally guided coronavirus nanoparticle vaccines to broaden CoV vaccine protection. This proposal utilizes our novel platform to develop potent, RBS-focused nanoparticle vaccines to induce broad protection across CoV lineages, escape mutations and potential pandemic CoVs that are of concern. The project aims are: (1) Create a library of mutants that escape coronavirus immunity (2) Develop RBS-focused nanoparticle vaccines to induce broadly neutralizing antibodies to conserved sites using nucleic acid delivery and (3) Develop vaccine regimens to induce broad immunity and protection across diverse CoVs.